Archive for October, 2008
The first family-based genome-wide association study in Alzheimer’s disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder.
More: continued here
Urgent action is needed to prevent a ’silent epidemic’ of alcohol-related dementia in the UK, psychiatrists have warned. Writing in the November issue of the British Journal of Psychiatry, two London-based psychiatrists with a special interest in dementia discuss the potential impact of increasing alcohol consumption among young and middle-aged people.
More: continued here
Four novel genes that may significantly increase the risk of the most common form of late-onset Alzheimer’s have been identified by researchers at Massachusetts General Hospital and Harvard Medical School, as reported in the November 7th issue of American Journal of Human Genetics.
More: continued here
Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer’s disease (AD). The newly published results of a major long-term study (J Neurol NeuroSurg Psychiatry Oct. 17, 2008) now provides powerful new evidence that taking statins substantially reduces the risk of AD.
More: continued here
Growing, the last book in Alzheimer’s Society’s Feelings Matter Most series, will be launched at the third national Dementia Congress in Bournemouth. The series challenges current practises and urges dementia care trainers to give dementia care the time it needs. Growing highlights the need to grow training from simple awareness raising to developing evidence-based learning.
More: continued here
New hope has been offered to thousands of people in the early stages of Alzheimer’s today, 29 October, following a landmark decision in the House of Lords. The Lord’s denied the National Institute for Health and Clinical Excellence (NICE) the right to appeal a high court decision which, in May 2008, ordered NICE to release a copy of the model it used to restrict Alzheimer’s drugs on the NHS.
More: continued here
Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, welcome the announcement by the House of Lords that they have refused the National Institute for Health and Clinical Excellence (NICE)’s application for leave to appeal against the Court of Appeal verdict handed down earlier this year.
More: continued here
Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), disrupt the quality of life for patients, put a tremendous burden on family caregivers, and cost society billions of dollars annually. The most consistent risk factor for developing neurodegenerative disease is aging.
More: continued here
A team of Université Laval researchers has shown that the main neurological markers for Alzheimer’s disease are exacerbated in the brains of mice fed a diet rich in animal fat and poor in omega-3s. Details of the study - which suggests that diets typical of most industrialized countries promote the development of Alzheimer’s - are outlined in the latest online edition of Neurobiology of Aging.
More: continued here
The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer’s Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed. The study, published in the Journal of Experimental Medicine, reveals that VPA works by inhibiting the activity of an enzyme that produces a neurotoxic protein called beta Amyloid. In doing so, plaque formation is discontinued.
More: continued here





